CD40 molecule (CD40) (CD40)

CD40 molecule (CD40), also known as Tumor Necrosis Factor Receptor Superfamily Member 5 (TNFRSF5), is a 48 kDa type I transmembrane glycoprotein that serves as a critical costimulatory receptor on professional antigen-presenting cells (APCs), including dendritic cells, B cells, and macrophages [1, 2]. Its primary biological role involves the "licensing" of APCs through interaction with CD40 ligand (CD40L or CD154) on activated T helper cells, which triggers intracellular signaling pathways like NF-κB and MAPK to enhance antigen presentation and cytokine production [3]. In the context of dendritic/tumor fusion cells, CD40 signaling is essential for the maturation and functional activation of these cellular vaccines, enabling them to effectively prime cytotoxic T lymphocytes against a broad array of tumor antigens [4]. Therapeutically, CD40 is a major target in oncology, where agonistic antibodies are used to stimulate anti-tumor immunity, and in autoimmunity, where antagonistic agents aim to block pathogenic B-cell and T-cell interactions [3, 5]. Clinical challenges associated with CD40-targeted therapies include systemic toxicities such as cytokine release syndrome and hepatotoxicity, necessitating careful dose optimization and the development of localized delivery strategies [5]. The use of CD40 agonists in combination with other immunotherapies, such as checkpoint inhibitors, is a significant area of ongoing clinical research [3]. Furthermore, CD40 expression on certain tumor cells themselves can be targeted to induce direct apoptosis or antibody-dependent cellular cytotoxicity [3].

Other names

TNFRSF5CDW40Bp50Tumor necrosis factor receptor superfamily member 5B-cell surface antigen CD40

Agonism of CD40 to activate antigen-presenting cells and enhance anti-tumor immunity; Antagonism of CD40 to inhibit B-cell and T-cell interactions in autoimmune diseases.